Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01506271
Recruitment Status : Completed
First Posted : January 9, 2012
Results First Posted : June 10, 2019
Last Update Posted : June 10, 2019
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The purpose of this study is to evaluate the efficacy, safety and tolerability of adding 125 mg or 250 mg doses of relebactam (MK-7655) to imipenem/cilastatin in adults 18 years or older with Complicated Intra-Abdominal Infection (cIAI). The primary hypothesis is that the relebactam + imipenem/cilastatin treatment regimen is non-inferior to treatment with imipenem/cilastatin alone with respect to the percentage of participants with a favorable clinical response at completion of intravenous (IV) study therapy.

Condition or disease Intervention/treatment Phase
Intra-abdominal Infections Drug: Relebactam 250 mg Drug: Relebactam 125 mg Drug: Imipenem/cilastatin Drug: Matching placebo to relebactam Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 351 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Intra-Abdominal Infection [cIAI]
Actual Study Start Date : June 1, 2012
Actual Primary Completion Date : August 12, 2014
Actual Study Completion Date : August 12, 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Relebactam 250 mg with imipenem/cilastatin
Participants randomized to receive relebactam 250 mg will be administered 250 mg doses of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
Drug: Relebactam 250 mg
Relebactam 250 mg IV every 6 hours for a minimum of 96 hours
Other Name: MK-7655

Drug: Imipenem/cilastatin
A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.

Experimental: Relebactam 125 mg with imipenem/cilastatin
Participants randomized to receive relebactam 125 mg will be administered 125 mg doses of relebactam IV, in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
Drug: Relebactam 125 mg
Relebactam 125 mg IV every 6 hours for a minimum of 96 hours
Other Name: MK-7655

Drug: Imipenem/cilastatin
A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.

Placebo Comparator: Placebo to relebactam with imipenem/cilastatin
Participants randomized to receive placebo for relebactam will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
Drug: Imipenem/cilastatin
A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.

Drug: Matching placebo to relebactam
Placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.




Primary Outcome Measures :
  1. Percentage of Participants With a Favorable Clinical Response at Completion of IV Study Therapy [ Time Frame: 4 to 14 days post initiation of intravenous (IV) study therapy (up to postrandomization Day 14) ]
    A favorable clinical response was assessed by the clinical investigator as a cure, and was defined as a situation where all or most pre-therapy signs and symptoms of the index infection had resolved, or returned to pre-infection status, and no additional antibiotic therapy was required.

  2. Percentage of Participants With an Elevated Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) Laboratory Values That Are Greater Than or Equal to 5X the Upper Limit of Normal (ULN) [ Time Frame: Up to 14 days following completion of all study therapy (up to Day 28) ]
    Pre-specified events of interest were confirmed (i.e., verified by repeat testing) elevated AST or ALT laboratory value that is greater than or equal to 5 X ULN as a result of within-protocol-specific testing or unscheduled testing.

  3. Percentage of Participants With Elevated AST or ALT Laboratory Values >= 3X the ULN, Total Bilirubin >= 2X the ULN, and Alkaline Phosphatase Values < 2X the ULN [ Time Frame: Up to 14 days following completion of all study therapy (up to Day 28) ]
    Pre-specified events of interest were a confirmed (i.e., verified by repeat testing) elevated AST or ALT laboratory value that is greater than or equal to 3X ULN, as well as elevated total bilirubin greater than or equal to 2X the ULN, and alkaline phosphatase values that are less than 2X the ULN, as a result of within-protocol-specific testing or unscheduled testing.

  4. Percentage of Participants With Any Adverse Event (AE) [ Time Frame: Up to 14 days following completion of all study therapy (up to Day 28) ]
    An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE.

  5. Percentage of Participants With Any Serious Adverse Event (SAE) [ Time Frame: Up to 14 days following completion of all study therapy (up to Day 28) ]
    A serious adverse event (SAE) is any AE occurring at any dose that is life threatening; results in a persistent or significant disability/incapacity; prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; or results in death.

  6. Percentage of Participants With Any Drug-related AE [ Time Frame: Up to 14 days following completion of all study therapy (up to Day 28) ]
    An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. A drug-related AE is a AE determined by the investigator to be possibly, probably or definitely related to drug treatment.

  7. Percentage of Participants With Any Drug-related SAE [ Time Frame: Up to 42 days following completion of all study therapy (up to Day 56) ]
    A SAE is any AE occurring at any dose that is life threatening; results in a persistent or significant disability/incapacity; prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; or results in death. A drug-related SAE is a SAE determined by the investigator to be possibly, probably or definitely related to drug treatment.

  8. Percentage of Participants Who Discontinued IV Study Therapy Due to an AE [ Time Frame: Up to 14 days post initiation of IV study therapy (up to 14 days) ]
    An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. AEs assessed by the investigator that caused discontinuation of participant treatment are presented.

  9. Percentage of Participants Who Discontinued IV Study Therapy Due to a Drug-related AE [ Time Frame: Up to 14 days post initiation of IV study therapy (up to 14 days) ]
    An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. A drug-related AE is an AE determined by the investigator to be possibly, probably or definitely related to drug treatment. Drug-related AEs assessed by the investigator that caused discontinuation of participant treatment are presented.

  10. Percentage of Participants With Specific AEs With Incidence of >= 4 Participants in One Treatment Group [ Time Frame: Up to 42 days following completion of all study therapy (up to Day 56) ]
    An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. AE preferred terms, with incidence greater than or equal to 4 in one treatment group are presented. AEs preferred terms which did not achieve this threshold are not reported. AE preferred terms are based on MedDRA version 17.0.

  11. Percentage of Participants With Predefined Limit of Change (PDLC) With Incidence of >= 4 Participants in One Treatment Group [ Time Frame: Up to 42 days following completion of all study therapy (up to Day 56) ]
    Predefined limit of change (PDLC) are presented based on values from the following laboratory tests on serum: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (Bil), and alkaline phosphatase (AP). Results are presented for PDLC from tests with reported incidence greater than or equal to 4 participants in one treatment group. Laboratory tests which did not achieve the PDLC threshold are not reported.

  12. Percentage of Participants With System Organ Class (SOC) With AEs With Incidence of >= 4 Participants in One Treatment Group [ Time Frame: Up to 42 days following completion of all study therapy (up to Day 56) ]
    A system organ class (SOC) is the highest level of terminology used to describe disorders of the human body, and distinguishes by either anatomical or physiological systems, disease origin or purpose. SOCs with AE incidence greater than or equal to 4 in one treatment group are presented. SOCs with AE incidence which did not achieve this threshold are not reported. SOCs are based on MedDRA version 17.0.


Secondary Outcome Measures :
  1. Percentage of Participants With a Favorable Clinical Response at Completion of IV Study Therapy in Participants Who Have Imipenem-resistant, Gram-negative cIAI Infections. [ Time Frame: 4 to 14 days post initiation of IV study therapy (up to postrandomization day 14). ]
    A favorable clinical response is assessed by the clinical investigator as a cure, and is defined as a situation where all or most pre-therapy signs and symptoms of the index infection have resolved, or returned to pre-infection status, and no additional antibiotic therapy is required.

  2. Percentage of Participants With a Favorable Clinical Response at Early Follow-up [ Time Frame: Up to 9 days following completion of all study therapy (up to Day 23) ]
    A favorable clinical response is assessed by the clinical investigator as a cure, and is defined as a situation where all or most pre-therapy signs and symptoms of the index infection have resolved, or returned to pre-infection status, and no additional antibiotic therapy is required.

  3. Percentage of Participants With a Favorable Microbiological Response at Completion of IV Study Therapy [ Time Frame: Up to 14 days post initiation of IV study therapy (up to postrandomization day 14) ]
    A favorable microbiological response is assessed by the clinical investigator, and is defined as the eradication or presumptive eradication of all bacterial pathogens identified at baseline.

  4. Percentage of Participants With a Favorable Microbiological Response at Early Follow-up [ Time Frame: Up to 9 days following completion of all study therapy (up to Day 23) ]
    A favorable microbiological response is assessed by the clinical investigator, and is defined as the eradication or presumptive eradication of all bacterial pathogens identified at baseline.

  5. Percentage of Participants With a Favorable Clinical Response at Late Follow-up [ Time Frame: Up to 42 days following completion of all study therapy (up to Day 56) ]
    A favorable clinical response is assessed by the clinical investigator as a cure, and is defined as a situation where all or most pre-therapy signs and symptoms of the index infection have resolved, or returned to pre-infection status, and no additional antibiotic therapy is required.

  6. Percentage of Participants With a Favorable Microbiological Response at Late Follow-up [ Time Frame: Up to 42 days following completion of all study therapy (up to Day 56) ]
    A favorable microbiological response is assessed by the clinical investigator, and is defined as the eradication or presumptive eradication of all bacterial pathogens identified at baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinically suspected and/or bacteriologically documented cIAI requiring hospitalization and treatment with IV antibiotic therapy.
  • Enrolled intraoperatively or postoperatively on the basis of operative findings OR enrolled preoperatively on the basis of compelling preoperative clinical findings.

Exclusion Criteria:

  • Infection which should be managed by Staged Abdominal Repair (STAR) or open abdomen technique.
  • Acute Physiology and Chronic Health Evaluation II (APACHE II) score greater than 30.
  • Any amount of effective antibiotic therapy after obtaining the culture for admission to this study and prior to the administration of the first dose of IV study therapy.
  • An infection which has been treated with >24 hours of systemic antibiotic therapy known to be effective against the presumed or documented etiologic pathogen(s) within the 72-hour period immediately prior to consideration for entry into the study.
  • History of serious allergy, hypersensitivity (e.g., anaphylaxis), or any serious reaction to carbapenem antibiotics, any cephalosporins, penicillins, or other β-lactam agents.
  • History of serious allergy, hypersensitivity (e.g., anaphylaxis), or any serious reaction to other β-lactamase inhibitors (e.g., tazobactam, sulbactam, clavulanic acid).
  • History of a seizure disorder (requiring ongoing treatment with anticonvulsive therapy or prior treatment with anti-convulsive therapy in the last 3 years).
  • Currently being treated with valproic acid or has used valproic acid in the 2 weeks prior to screening.
  • Rapidly progressive or terminal illness (unlikely to survive the approximately 6- to 8-week study period).
  • Pregnant or expecting to conceive, breastfeeding, or plans to breast feed within 1 month of completion of the study.
  • Participant in whom a response to IV study therapy within the timeframe of treatment specified in this protocol is considered unlikely.
  • Concurrent infection that would interfere with evaluation of response to the study antibiotics.
  • Need for concomitant systemic antimicrobial agents in addition to those designated in the various study treatment groups.
  • cIAI due to a confirmed fungal pathogen.
  • Currently receiving immunosuppressive therapy, including use of high-dose corticosteroids.
  • Prior recipient of a renal transplantation.
  • Estimated or actual creatinine clearance of <50 mL/minute.
  • History of any other illness that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering the study drug to the patient.
  • Laboratory abnormalities as specified in protocol.
  • Currently participating in, or has participated in any other clinical study involving the administration of investigational or experimental medication (not licensed by regulatory agencies) at the time of presentation or during the previous 30 days prior to screening or is anticipated to participate in such a clinical study during the course of the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01506271


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme Corp.

Publications of Results:
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01506271    
Other Study ID Numbers: 7655-004
2011-005686-20 ( EudraCT Number )
MK-7655-004 ( Other Identifier: Merck Protocol Number )
First Posted: January 9, 2012    Key Record Dates
Results First Posted: June 10, 2019
Last Update Posted: June 10, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php
Keywords provided by Merck Sharp & Dohme Corp.:
Complicated Intra-abdominal Infections
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Intraabdominal Infections
Imipenem
MK-7655
Cilastatin
Anti-Bacterial Agents
Anti-Infective Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
beta-Lactamase Inhibitors